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Clinical practice guidelines have been developed by professional societies globally. Each guideline although based on published 
scientific evidence reflected each country’s socioeconomic peculiarities and unique medical environment. The Society of 
Obstetrics and Gynaecology of Nigerian has published guidelines in other clinical areas; however, this is the first edition of 
practice guidelines for the prevention of cervical cancer. The Guidelines Committee was established in 2015 and decided 
to develop the first edition of this guideline following Delphi pool conducted among members which selected cervical cancer 
prevention as the subject that guideline is urgently needed. These guidelines cover strategies for cervical cancer prevention, 
screening, and management of test results. The committee developed the draft guideline during a two‑day workshop with 
technical input from Cochrane Nigeria and Dr. Chris Maske, Lancet Laboratories, South Africa. The recommendations for each 
specific area were developed by the consensus, and they are summarized here, along with the details. The objective of these 
practice guidelines is to establish standard policies on issues in clinical practice related to the prevention of cervical cancer.
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Introduction
The cancer of the uterine cervix is the second most common 
cancer in Nigerian women.[1-3] In 2012, Nigeria recorded 14,089 
new cervical cancer cases and 8240 deaths.[3] Most of the cases 
were squamous cell carcinoma followed by adenocarcinomas.
Human papillomavirus (HPV) is the main etiological agent 
for the development of cervical cancer, with HPV serotypes 
16 and 18 accounting for over 70% of cases.[4-6] HPV is also 
responsible for an important fraction of other anogenital, 
head-and-neck cancer.
Cervical cancer is preventable through the use of HPV vaccine 
and curable if diagnosed early. Unfortunately, the majority of 
the cases in Nigeria present at late stages 3 and 4, when the 
disease is only amenable to radiotherapy. The inadequate 
radiotherapy facilities in the country compound the late 
presentation giving the women almost no chance at survival.
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Prevention and treatment of cervical cancer is crippled by 
lack of awareness and knowledge of the disease, suboptimal 
public investment and competing health needs, etc., There is 
no adequate central database for cervical cancer in Nigeria. 
There is no organized national screening programme for 
cervical cancer, and the National Health Insurance Scheme 
has limited coverage for cancer treatment. The few existing 
cervical cancer screening programs are opportunistic and 
are based on Pap smear with its technological and human 
resource challenge and visual inspection with acetic or Lugol’s 
iodine (VIA/VILI) with its challenge of low-test characteristics.
The ideal strategy for cervical cancer prevention and 
treatment in Nigeria should have the potential to prevent 
HPV infection, overcome the limitations of existing screening 
tools, and identify cases early. HPV vaccination of young girls 
and HPV-based cervical cancer screening methods has the 
potential to address these gaps.
Globally, high-risk HPV (hrHPV) has been detected in 96.6% 
of patients with invasive cervical cancer. Testing for hrHPV, 
therefore, has a key role in cervical cancer screening. HPV 
infection can be prevented by the use of HPV vaccines. There 
are three types of vaccines currently available. Two of the 
three the bivalent HPV vaccine (HPV16/18) and quadrivalent 
HPV vaccine (HPV6/11/16/18) are licensed for use in Nigeria. 
The nonavalent HPV vaccine (HPV6/11/16/18/31/33/45/52/58) 
is not yet licensed for use in Nigeria.
 Primary Prevention
In Nigeria, cervical cancer screening is opportunistic 
and in-efficient in many parts of the country where the 
appropriate infrastructure is missing. Therefore, avoiding HPV 
infection should be the mainstay of cervical cancer prevention 
using the strategies of health education and vaccination for 
all women up to the age of 26 years.
Target population: The general population
The specific interventions for primary prevention of cervical 
cancer include:
1. Health education: health education and counseling for 
policymakers, parents, guardians, young girls/boys and 
women/men to practice safe sex, and delayed sexual 
debut and benefits of HPV vaccination
2. Use of prophylactic vaccination against HPV: The three 
HPV vaccines that offer protection against HPV types 16 
and 18 (the two most common strains in cervical cancer) 
which account for about 70% of cervical cancer are 
available. While the bivalent offer protection against HPV 
16, 18, the quadrivalent and nonavalent offer protection 
against HPV 6, 11, 16, 18 and HPV 6, 11, 16,18, 31, 33, 
45, 52, 58 respectively. Nonavalent vaccine is estimated 
that it could prevent 87% of cervical cancers globally in 
women who are naïve to HPV infection. As the current 
vaccines cannot offer full protection, cervical cancer 
screening is still very relevant even among vaccinated 
individuals. These prophylactic vaccines work best for 
young girls before they are exposed to HPV infection 
through sexual intercourse and should be the target 
population for HPV vaccination. The World Health 
Organization recommends the primary target population 
to be girls within the age range of 9 or 10 years through 
to 13 years. It further recommends a two-dose schedule 
with a 6-month interval between the doses for females 
younger than 15 years because avail evidence has shown 
that antibody response to two doses in 9–14 years old 
girls is as good as a three-dose course. The anti-HPV 
immune responses for all nine types in girls and boys 
9–14 years of age who received two doses are the same 




schedule with a 6-month interval between the doses (0, 
6 months)
•	 Women	age	16–26	years	can	be	given	a	3‑dose	regime	
(0,1, and 6 months or 0, 2, and 6 months)
•	 HPV	vaccine	should	not	be	given	to	pregnant	women




The current available HPV vaccines provide only partial 
protection against cervical cancer; Vaccinated women should 
still undergo screening. As the impact of HPV vaccines on 
cervical cancer will take a while to be observed in the country 
considering that it is an infancy level, secondary prevention 
by cervical cancer screening will still remain a key prevention 
strategy in the foreseeable future.
The primary objective of secondary prevention of cervical 
cancer is the accurate detection and timely treatment of 
precancerous lesions. Cytology, visual inspection, and HPV 
testing are three screening strategies for cervical cancer 
screening. HPV testing has the highest sensitivity.
This guideline recognizes the following limitations associated 
with cytology-based screening program.
•	 Shortage	of	cytopathologists
•	 Prolonged	turnaround	time
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•	 Multiple	visits
•	 Loss	to	follow‑up.




HPV testing, which is more sensitive than the cytology-based 
screening test, can be introduced without cytopathologist 
have the potential to bridge-resource gaps.
Target population for screening: the target population is all 
women between age 25 and 65 years. Cervical cancer rarely 
occurs in women below 25 years in our environment and the 
high proportion of cytological abnormalities that regresses 
spontaneous below this age, screening before this age is less 
cost-effective and could result in unnecessary interventions. 
However, women aged below 25 years and at high-risk for 
cervical cancer may be screened after assessment by a physician.
Although cervical cancer screening has not usually been 
offered during pregnancy, however, in our environment, it 
may be the only opportunity, and it should be offered. Women 
who have hysterectomy with removal of cervix for benign 
diseases and without a prior history of cervical dysplasia can 
discontinue screening.
Methods of screening
The guideline recommends that HPV testing should be 
adopted as the primary screening strategy [Figure 1].
Where HPV testing is not available, alternative screening 
methods include VIA/VILI [Figure 2] and cytology [Figure 3].
HPV Testing should only target hrHPV. Testing for low-risk 
HPV types has no clinical role in cervical cancer screening. As 
the performance characteristics vary among these HPV tests, 
only analytically and clinically validated HPV tests should be 
used. Laboratory standard operating procedures and quality 
assurance programs should be in place for the use of any HPV 
testing procedures.
Treatment of precancerous cervical lesion
Excisional and ablative methods are available for treatment of 
precancerous cervical lesion. Excisional methods have the added 
advantage of tissue preservation for histology. This guideline 
recommends excisional methods are the preferred option.
Figure 1: Management of women with high‑risk human papillomavirus test result
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Recommendation for secondary prevention
•	 Screening	should	start	at	25	years	of	age
•	 Women	of	 age	<25	 years	 at	 high	 risk	 of	 developing	
cervical cancer as determined by a physician




negative during follow-up should revert to the initial 
5 year HPV testing interval
•	 Routine	HPV	testing	should	be	stopped	at	age	60	 for	
patients who have been on the routine or have had 
prior HPV tests, otherwise below 65 years who had not 
previously tested should undergo testing
•	 Management	of	the	result	of	HPV	testing	should	follow	
the algorithm in Figure 1
•	 The	finding	of	HPV	16	and	18	in	HPV	testing	requires	
immediate colposcopy. However, if colposcopy is not 
available, VIA or cytology, and biopsy is recommended
•	 The	finding	of	high‑risk	HPV	serotypes	other	than	HPV	
16 and 18, VIA or cytology is recommended
•	 Colposcopy	is	indicated	for	women	with	hrHPV‑positive	
test and ASCUS-H cytology result
•	 Women	 presenting	 with	 ASCUS	 cytology	 and	
hrHPV-negative can be followed up at 1 year
•	 Women	 presenting	with	 negative	 cytology	 at	 first	
screening should be offered HPV testing in 1 year
•	 A	 5‑year	 screening	 interval	 is	 recommended	 after	 a	
negative HPV testing and negative cytology
•	 HPV	testing	should	be	offered	during	pregnancy.
Special Consideration
1. Women starting with Pap smear
 a. If normal/LSIL, offer HPV testing in 1 year
 b.  If positive for ASCUS-H/HSIL, perform colposcopy, 
and biopsy.
2. Women starting with VIA/VILI
 a. If negative, offer HPV testing in 1 year
 b.  If positive, offer immediate HPV testing and manage 
as per protocol.
3. Women living with HIV infection HIV positive women 
are at a higher risk of persistent HPV infection, rapid 
progression of precancerous lesion to invasive cervical 
cancer. After a negative HPV testing, it can be repeated 
3 yearly.
Figure 2: Management women presenting with and visual inspection with acetic or Lugol’s iodine result
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